Timbo. Seems things have changed since last investor call.
From this ANN:
Following the discussion on the Company’s lead program, PYC’s CEO, Rohan Hockings will
provide an update on progress in the Company’s:
- Second drug development candidate – a first-in-class therapy in another blinding
eye disease called Autosomal Dominant Optic Atrophy that is expected to enter
human trials next year; and
- Third drug development candidate – a first-in-class therapy for a
neurodevelopmental disorder known as Phelan McDermid Syndrome.
Timbo. Seems things have changed since last investor call.From...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.3¢ | 12.0¢ | $624.5K | 5.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1227634 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 130000 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |